Cytek Biosciences, Inc. Common Stock
CTKBCytek Biosciences, Inc. is a biotechnology company specializing in developing and manufacturing advanced spectral flow cytometry instruments. Founded to improve cellular analysis, it offers innovative solutions for research and clinical laboratories, enabling detailed immune profiling and cellular characterization through high-parameter, multicolor flow cytometry systems.
Company News
Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument...
Cytek Biosciences was recognized by TIME and Statista as one of America's top-performing publicly listed companies, highlighting its exceptional growth, financial stability, and innovative cell analysis solutions.
Cytek Biosciences' Muse Micro cell analyzer won the 2025 BioTech Breakthrough Award for Drug Discovery Solution of the Year, highlighting its innovative approach to making cell analysis more accessible and cost-effective for laboratories.
Cytek Biosciences is launching a two-part research support initiative to make cell analysis more accessible, including awarding a flow cytometer and planning a research grant program in collaboration with ISAC to support scientific research globally.
Cytek Biosciences relocates and expands its European headquarters in Amsterdam, increasing its facility footprint by over 40% and establishing a dedicated customer service and training center to strengthen its presence in the EMEA region.
